Peter A. Thompson
CIK 1357522 · Interim Chief Exec Officer · last filed 2026-05-29
Peter A. Thompson is an Interim Chief Exec Officer who has filed 122 SEC Form 4 insider transactions across 15 companies since 2007. The most recent filing shows the insider sold $4.5K of SION on May 29, 2026. Across all open-market trades the lifetime net is +$80.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.29B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.29B
15
122
$80.10M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SION | Director | 2,671,721 | $35.92 | $95.97M | -$36.65M | 10 | 2026-05-29 |
| CRVS | Director | 8,684,091 | $11.93 | $103.60M | $10.58M | 29 | 2026-01-30 |
| SPRY | Director | 269,323 | $9.76 | $2.63M | -$9.49M | 6 | 2025-06-27 |
| EWTX | Director | 443,792 | $34.83 | $15.46M | $26.74M | 9 | 2025-06-18 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 0 | $64.97 | $0 | -$25.72M | 14 | 2024-05-20 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 327,852 | $4.91 | $1.61M | $30.00M | 3 | 2022-06-21 |
| JANX | Director | 231,098 | $13.56 | $3.13M | $1.41M | 6 | 2022-06-16 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 952,377 | $5.87 | $5.59M | $25.00M | 4 | 2022-06-13 |
| PMVP | Director | 114,039 | $1.11 | $126.6K | $17.10M | 2 | 2021-06-09 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 12,940,111 | — | — | $15.00M | 2 | 2020-06-19 |
| Synthorx, Inc. (THOR) Delisted | Director | 0 | — | — | $15.00M | 4 | 2020-01-24 |
| ASND | Director | 4,902,910 | $218.06 | $1.07B | $8.09M | 8 | 2018-06-06 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,989,949 | — | — | $2.98M | 1 | 2015-07-21 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 2 | 2012-05-10 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | President and CEO | 386,419 | — | — | $50.3K | 5 | 2009-08-28 |
Recent Filings
122 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-29 | SION | Sell (S) | −101 | -$4.5K | EDGAR |
| 2026-05-11 | SION | Sell (S) | −292,952 | -$13.36M | EDGAR |
| 2026-04-21 | SION | Sell (S) | −55,345 | -$2.47M | EDGAR |
| 2026-04-16 | SION | Sell (S) | −510,583 | -$22.95M | EDGAR |
| 2026-02-04 | SION | Sell (S) | −30,953 | -$1.38M | EDGAR |
| 2026-01-30 | CRVS | Exer (M) | +210,000 | $1.12M | EDGAR |
| 2025-12-29 | SION | Sell (S) | −33,356 | -$1.49M | EDGAR |
| 2025-12-19 | SION | Sell (S) | −1,875 | -$83.4K | EDGAR |
| 2025-11-26 | SION | Sell (S) | −108,073 | -$4.81M | EDGAR |
| 2025-07-01 | CRVS | Mixed | +221,352 | -$0 | EDGAR |